Amber Lee Southwell

Amber Lee Southwell

Auto-generated profile, based on publicly available information

Amber Lee Southwell

Burnett School of Biomedical Sciences, University of Central Florida, Orlando, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2011 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
TLTinh N. Luong
Tinh N. Luong
HCHolly J. Carlisle
Holly J. Carlisle
ASAmber Southwell
Amber Southwell
PPPaul H. Patterson
Paul H. Patterson
Deficits in fine motor coordination can be assessed with the balance beam test. Performance on the beam is quantified by the speed at...

1 December 2011 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
JCJeffrey B Carroll
Jeffrey B Carroll
SWSimon C Warby
Simon C Warby
ASAmber L Southwell
Amber L Southwell
CDCrystal N Doty
Crystal N Doty
SGSarah Greenlee
Sarah Greenlee
MHMichael R. Hayden
Michael R. Hayden
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG-expansion in the huntingtin gene (HTT) that results in a toxic gain of function in the mutant huntingtin protein (mHTT). Reducing the expression of mHTT is therefore an attractive therapy for HD. However, wild-type HTT protein is essential for development and has critical roles in maintaining neuronal health. Therapies for HD that reduce wild-type HTT may therefore generate unintended negative consequences. We have identified single-nucleotide polymorphism (SNP) targets in the human HD population for the disease-specific targeting of the HTT gene. Using primary cells from patients with HD and the transgenic YAC18 and BACHD mouse lines, we developed antisense oligonucleotide (ASO) molecules that potently and selectively silence mHTT at both exonic and intronic SNP sites. Modification of these ASOs with S-constrained-ethyl (cET) motifs significantly improves potency while maintaining allele selectively in vitro. The developed ASO is potent and selective for mHTT in vivo after delivery to the mouse brain. We demonstrate that potent and selective allele-specific knockdown of the mHTT protein can be achieved at therapeutically relevant SNP sites using ASOs in vitro and in vivo.

8 August 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MZMark J. Zylka
Mark J. Zylka
XDXinzhong Dong
Xinzhong Dong
ASAmber L. Southwell
Amber L. Southwell
DADavid J. Anderson
David J. Anderson
The Mas-related genes ( Mrgs ) comprise a family of >50 G protein-coupled receptors (GPCRs), many of which are expressed in specific subsets of nociceptive sensory neurons in mice. In contrast, humans contain a related but nonorthologous family of genes, called MrgXs or sensory neuron-specific receptors, of which many fewer appear to be expressed in sensory neurons. To determine whether the diversity of murine Mrgs is generic to rodents or is an atypical feature of mice, we characterized MrgA, MrgB, MrgC , and MrgD subfamilies in rat and gerbil. Surprisingly, although mice have ≈22 MrgA and ≈14 MrgC genes, rats and gerbils have just a single MrgA and MrgC gene. This murine-specific expansion likely reflects recent retrotransposon-mediated unequal crossover events. The expression of Mrgs in rat sensory ganglia suggests that the extensive cellular diversity in mice can be simplified to a core subset of approximately four different genes ( MrgA, MrgB, MrgC , and MrgD ), defining a similar number of neuronal subpopulations. Our results suggest more generally that mouse–human genomic comparisons may sometimes reveal differences atypical of rodents.

23 March 2005 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
CCChi-Sung Chiu
Chi-Sung Chiu
SBStephen Brickley
Stephen Brickley
KJKimmo Jensen
Kimmo Jensen
ASAmber Southwell
Amber Southwell
SMSheri Mckinney
Sheri Mckinney
HLHenry A. Lester
Henry A. Lester
GABA transporter subtype 1 (GAT1) knock-out (KO) mice display normal reproduction and life span but have reduced body weight (female, -10%; male, -20%) and higher body temperature fluctuations in the 0.2-1.5/h frequency range. Mouse GAT1 (mGAT1) KO mice exhibit motor disorders, including gait abnormality, constant 25-32 Hz tremor, which is aggravated by flunitrazepam, reduced rotarod performance, and reduced locomotor activity in the home cage. Open-field tests show delayed exploratory activity, reduced rearing, and reduced visits to the central area, with no change in the total distance traveled. The mGAT1 KO mice display no difference in acoustic startle response but exhibit a deficiency in prepulse inhibition. These open-field and prepulse inhibition results suggest that the mGAT1 KO mice display mild anxiety or nervousness. The compromised GABA uptake in mGAT1 KO mice results in an increased GABAAreceptor-mediated tonic conductance in both cerebellar granule and Purkinje cells. The reduced rate of GABA clearance from the synaptic cleft is probably responsible for the slower decay of spontaneous IPSCs in cerebellar granule cells. There is little or no compensatory change in other proteins or structures related to GABA transmission in the mGAT1 KO mice, including GAT1-independent GABA uptake, number of GABAergic interneurons, and GABAA-, vesicular GABA transporter-, GAD65-, and GAT3-immunoreactive structures in cerebellum or hippocampus. Therefore, the excessive extracellular GABA present in mGAT1 KO mice results in behaviors that partially phenocopy the clinical side effects of tiagabine, suggesting that these side effects are inherent to a therapeutic strategy that targets the widely expressed GAT1 transporter system.

28 October 2009 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ASAmber L. Southwell
Amber L. Southwell
JKJan Ko
Jan Ko
PPPaul H. Patterson
Paul H. Patterson
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease resulting from the expansion of a glutamine repeat in the huntingtin (Htt) protein. Current therapies are directed at managing symptoms such as chorea and psychiatric disturbances. In an effort to develop a therapy directed at disease prevention we investigated the utility of highly specific, anti-Htt intracellular antibodies (intrabodies). We previously showed that VL12.3, an intrabody recognizing the N terminus of Htt, and Happ1, an intrabody recognizing the proline-rich domain of Htt, both reduce mHtt-induced toxicity and aggregation in cell culture and brain slice models of HD. Due to the different mechanisms of action of these two intrabodies, we then tested both in the brains of five mouse models of HD using a chimeric adeno-associated virus 2/1 (AAV2/1) vector with a modified CMV enhancer/chicken β-actin promoter. VL12.3 treatment, while beneficial in a lentiviral model of HD, has no effect on the YAC128 HD model and actually increases severity of phenotype and mortality in the R6/2 HD model. In contrast, Happ1 treatment confers significant beneficial effects in a variety of assays of motor and cognitive deficits. Happ1 also strongly ameliorates the neuropathology found in the lentiviral, R6/2, N171-82Q, YAC128, and BACHD models of HD. Moreover, Happ1 significantly prolongs the life span of N171-82Q mice. These results indicate that increasing the turnover of mHtt using AAV-Happ1 gene therapy represents a highly specific and effective treatment in diverse mouse models of HD.

19 August 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MØMichael E. Østergaard
Michael E. Østergaard
ASAmber L. Southwell
Amber L. Southwell
HKHolly Kordasiewicz
Holly Kordasiewicz
AWAndrew T. Watt
Andrew T. Watt
NSNiels H. Skotte
Niels H. Skotte
PSPunit P. Seth
Punit P. Seth
Autosomal dominant diseases such as Huntington’s disease (HD) are caused by a gain of function mutant protein and/or RNA. An ideal treatment for these diseases is to selectively suppress expression of the mutant allele while preserving expression of the wild-type variant. RNase H active antisense oligonucleotides (ASOs) or small interfering RNAs can achieve allele selective suppression of gene expression by targeting single nucleotide polymorphisms (SNPs) associated with the repeat expansion. ASOs have been previously shown to discriminate single nucleotide changes in targeted RNAs with ∼5-fold selectivity. Based on RNase H enzymology, we enhanced single nucleotide discrimination by positional incorporation of chemical modifications within the oligonucleotide to limit RNase H cleavage of the non-targeted transcript. The resulting oligonucleotides demonstrate >100-fold discrimination for a single nucleotide change at an SNP site in the disease causing huntingtin mRNA, in patient cells and in a completely humanized mouse model of HD. The modified ASOs were also well tolerated after injection into the central nervous system of wild-type animals, suggesting that their tolerability profile is suitable for advancement as potential allele-selective HD therapeutics. Our findings lay the foundation for efficient allele-selective downregulation of gene expression using ASOs—an outcome with broad application to HD and other dominant genetic disorders.